Clinical trials: Renal Carcinoma
Metastatic Renal Cell Carcinoma
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether the experimental vaccine G250 with or without IL-2 can produce an immune response in patients with renal cell carcinoma who have had all their cancer removed by surgery.
- Trial name
- NCT00203866
- Testing
- G250 peptide, IL-2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Chicago
Renal Cell Carcinoma, Bladder Cancer
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside
Immune checkpoint inhibitors (ICIs) are largely prescribed in a growing number of cancer diseases and at earlier stages (non metastatic cancer).
- Conditions
- Renal Cell Carcinoma, Bladder Cancer, MSI-H Cancer, Cancer
- Trial name
- VICKI (NCT06020651)
- Testing
- Arterial Doppler for Flow Mediated Reserve measurement
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Institut Mutualiste Montsouris
Metastatic Renal Cell Carcinoma
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
This is a prospective, single-arm, monocentric translational study designed to evaluate possible biomarkers of resistance to the first line of therapy with pazopanib in patients with metastatic renal cell carcinoma (mRCC) who…
- Trial name
- PIPELINE (NCT04462445)
- Testing
- Pazopanib
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Clear Cell Renal Cell Carcinoma
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell…
- Trial name
- eVOLVE-RCC02 (NCT07000149)
- Testing
- Volrustomig, Casdatifan
- Where
- 3 sites in Australia, South Korea
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT02072044
- Testing
- Anlotinib
- Where
- 15 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Kidney Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced kidney cancer.
- Trial name
- NCT03540199
- Testing
- Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer, cryotherapy
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts
- Trial name
- NCT05725421
- Testing
- Donor Radical and Partial Nephrectomy, Kidney Transplantation, Laparoscopic Radical Nephrectomy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Female Breast Carcinoma
The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer
Objective: Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer.
- Trial name
- leptin (NCT01643148)
- Volunteers
- 88 people
- Sponsor
- Materno-Perinatal Hospital of the State of Mexico
Kidney Tumor, Renal Cancer
Decision Aid (DA) for Renal Patients
The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses.
- Trial name
- NCT05387863
- Testing
- Decision Aid (DA) Web Tool, Institutional Pamphlet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- NYU Langone Health
Clear Renal Cell Cancer (< 7cm Size)
Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers
For the appropriate individualized treatment of T1-stage renal cell carcinoma with heterogeneous biological features, the expression of PBRM1, SETD2, BAP1, KDM5C and the newly proposed FOXC2 and CLIP4, are compared with clinical…
- Trial name
- NCT03694912
- Testing
- Partial or radical nephrectomy
- Where
- South Korea
- Volunteers
- 426 people
- Sponsor
- Yonsei University
Kidney Cancer, Leukemia
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
RATIONALE: A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy, or that have become cancer.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00303719
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 342 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma
- Trial name
- NCT04940299
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Ewing Sarcoma, Rhabdomyosarcoma
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other…
- Conditions
- Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT02581384
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma
Everolimus indirectly inhibits angiogenesis by reducing VEGF production. VEGF can be non-invasively visualized and quantified with serial 89Zr-bevacizumab PET imaging in patients.
- Trial name
- Everolimage (NCT01028638)
- Testing
- 89Zr-bevacizumab PET scan
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- University Medical Center Groningen
Carcinoma, Renal Cell, Tumor Thrombus
Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion
The goal of this observational study is to establish a preoperative imaging diagnostic model which highly consistent with the histopathological examinations, as well as a accurate and systematic pathological grading standard of…
- Conditions
- Carcinoma, Renal Cell, Tumor Thrombus, Neoplasm Invasiveness, Inferior Vena Cava Interruption
- Trial name
- NCT05589207
- Testing
- Vascular wall invaded
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Peking University Third Hospital
Renal Cell Carcinoma (RCC)
To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer
This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in…
- Trial name
- NCT07647744
- Testing
- Anti-Human CD70 T-Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Renal Cancers
Cryoablation Versus Radiofrequency Ablation for Small Renal Masses
The purpose of this study is to verify the oncological efficacy and safety of cryoablation and radiofrequency ablation for the treatment of small renal tumors.
- Trial name
- NCT00922948
- Testing
- Cryoablation, Radiofrequency ablation
- Where
- Canada
- Sponsor
- St. Joseph's Healthcare Hamilton
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022633
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 92 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.